ArticleFrontiers in immunology2026
Profiling complement proteins in pediatric tuberculosis children with or without serological evidence of prior SARS-CoV-2 exposure.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Coinfection with Methods: This study aimed to investigate complement activation in TB in children with or without serological evidence of prior SARS-CoV-2 exposure. Children aged 2-17 years with pulmonary or extrapulmonary TB were recruited from two tertiary hospitals in South India. Participants were grouped based on SARS-CoV-2 IgG serostatus: CoV2⁺ (n = 30) and CoV2⁻ (n = 30). Blood samples were collected at baseline, and at months 3, and 6 for complement profiling. Levels of classical, lectin, and alternative pathway proteins, as well as regulatory factors, were quantified using multiplex bead-based assays. Canonical discriminant analysis (CDA) and Spearman correlation were used to analyse temporal and relational patterns in complement activation. Results: CoV2 Discussion: SARS-CoV-2 seropositivity may contribute to changes in the complement activation trajectory in TB-diseased children, potentially contributing to persistent inflammation. Complement profiling may inform therapeutic strategies and serve as a biomarker of immune recovery in TB- SARS-CoV-2 co-infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.